China Pharma (CPHI) Announces Quarterly Earnings Results

China Pharma (NYSEAMERICAN:CPHI) posted its quarterly earnings data on Wednesday. The company reported ($0.01) earnings per share (EPS) for the quarter, RTT News reports. The business had revenue of $2.93 million during the quarter.

CPHI traded down $0.02 on Thursday, hitting $0.32. The company had a trading volume of 24,665 shares, compared to its average volume of 763,060. China Pharma has a 1-year low of $0.19 and a 1-year high of $0.84.

An institutional investor recently raised its position in China Pharma stock. Renaissance Technologies LLC raised its holdings in shares of China Pharma Holdings, Inc. (NYSEAMERICAN:CPHI) by 55.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 778,938 shares of the company’s stock after buying an additional 278,500 shares during the quarter. Renaissance Technologies LLC owned about 1.79% of China Pharma worth $258,000 as of its most recent SEC filing.

ILLEGAL ACTIVITY WARNING: “China Pharma (CPHI) Announces Quarterly Earnings Results” was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The original version of this piece of content can be read at

China Pharma Company Profile

China Pharma Holdings, Inc engages in the development, manufacture, and marketing of pharmaceutical products. It caters people with cardiovascular, central nervous system, infectious, and digestive diseases. The company was founded by Zhi Lin Li on January 28, 1999 and is headquartered in Haikou, China.

Featured Article: Why do companies engage in swaps?

Earnings History for China Pharma (NYSEAMERICAN:CPHI)

Receive News & Ratings for China Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Pharma and related companies with's FREE daily email newsletter.

Leave a Reply